Q3 2024 Pfizer Inc Earnings Call Transcript
Key Points
- Pfizer Inc (PFE) reported strong financial performance with a 32% operational growth in total company revenues for the third quarter of 2024.
- The company raised its full-year 2024 revenue guidance by $1.5 billion and adjusted diluted earnings per share by $0.30.
- Pfizer's oncology segment delivered a 31% year-over-year growth, driven by strong demand for products like XTANDI and TALZENNA.
- The company is making significant advancements in its pipeline, particularly in oncology and vaccines, with multiple Phase III trials underway.
- Pfizer's cost-reduction programs are creating a more efficient organization, setting the stage for increased capital returns and supporting dividend growth.
- Pfizer Inc (PFE) faces challenges with the integration of Seagen, although it has retained the majority of legacy Seagen colleagues.
- The company is experiencing headwinds from the discontinuation of OXBRYTA, impacting its non-COVID revenue guidance.
- There is uncertainty regarding the long-term impact of the Inflation Reduction Act (IRA) and Part D redesign on Pfizer's business.
- Pfizer's COVID-19 vaccine, COMIRNATY, contributed less to revenue compared to previous years, reflecting a stabilization in demand.
- The company is under pressure from activist investors, such as Starboard Value, who have expressed dissatisfaction with Pfizer's total shareholder return and capital deployment strategy.
(Operator Instructions) Good day, everyone, and welcome to Pfizer's third-quarter 2024 earnings conference call. Today's call is being recorded. At this time, I would like to turn the call over to Francesca DeMartino, Chief Investor Relations Officer and Senior Vice President. Please go ahead, ma'am.
Good morning, and welcome to Pfizer's earnings call. I'm Francesca DeMartino, Chief Investor Relations Officer. On behalf of the Pfizer team, thank you for joining us. This call is being made available via audio webcast at pfizer.com. Earlier this morning, we released our results for the third quarter of 2024 via a press release that is available on our website at pfizer.com.
I'm joined today by Dr. Albert Bourla, our Chairman and CEO; and Dave Denton, our CFO. Albert and Dave have some prepared remarks, and we will then open the call for questions. Members of our leadership team will be available for the Q&A session, including Dr. Andrew Baum, who recently joined
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
